Plant Name: Thymus quinquecostatus
Taxonomic Information:
Plant ID: NPO12935
Plant Latin Name: Thymus quinquecostatus
Taxonomy Genus: Thymus
Taxonomy Family: Lamiaceae
Plant External Links:
NCBI TaxonomyDB:
228974
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMMedicinal Functions:
Antiseptic; Deodorant; Disinfectant
Geographical Distribution:
China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CHRM1; HRH1; ADRA2C; ADRA1D; ADRA2A; ADRA2B; CHRM2; CHRM3; CHRM4; CHRM5; HTR2B; HTR2A; HTR2C; HTR6; DRD1; DRD3; | |
| TSHR; NPSR1; | |
| ACHE; | |
| ALPL; TDP1; PKM; NOX4; ALOX12; HSD17B1; HSD17B2; HSD17B10; APEX1; POLB; | |
| MET; MAPK1; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; CSNK2A1; | |
| CA2; CA12; CA14; CA7; CA4; | |
| ESR2; | |
| TYR; | |
| KDM4E; | |
| MMP12; MMP9; MMP1; MMP2; | |
| AHR; TP53; HIF1A; NFKB1; | |
| FUT7; | |
| SLC6A2; SLC6A4; | |
| FABP4; LMNA; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLC6A4 | Serotonin transporter | P31645 | CHEMBL228 |
| Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
| Small molecule receptor (family A GPCR) | HRH1 | Histamine H1 receptor | P35367 | CHEMBL231 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA1D | Alpha-1d adrenergic receptor | P25100 | CHEMBL223 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | CHRM2 | Muscarinic acetylcholine receptor M2 | P08172 | CHEMBL211 |
| Small molecule receptor (family A GPCR) | CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 | CHEMBL245 |
| Small molecule receptor (family A GPCR) | CHRM4 | Muscarinic acetylcholine receptor M4 | P08173 | CHEMBL1821 |
| Small molecule receptor (family A GPCR) | CHRM5 | Muscarinic acetylcholine receptor M5 | P08912 | CHEMBL2035 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0007197; adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway | 3.688E-13 | 5.772E-10 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0016907; G-protein coupled acetylcholine receptor activity | 3.688E-13 | 5.772E-10 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.155E-12 | 1.198E-09 | ADRA1D, ADRA2A, ADRA2B, ADRA2C, AXL, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD3, FLT3, HRH1, HTR2A, HTR2B, HTR2C, HTR6, IGF1R, KDR, MET, NPSR1, SLC6A2, SLC6A4, TSHR |
| BP | GO:0050896; response to stimulus | GO:0007207; phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway | 2.207E-12 | 2.002E-09 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 5.617E-12 | 4.077E-09 | ADRA1D, ADRA2A, ALOX12, CDK1, CHRM1, CSNK2A1, DRD3, FLT3, HIF1A, HTR2A, HTR2B, IGF1R, KDR, MAPK1, MMP12, MMP2, MMP9, PIM1, THPO, TSHR |
| MF | Unclassified; | GO:0004872; receptor activity | 1.014E-11 | 6.495E-09 | ADRA1D, ADRA2A, ADRA2B, ADRA2C, AHR, AXL, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD3, ESR2, FLT3, HRH1, HTR2A, HTR2B, HTR2C, HTR6, IGF1R, KDR, MET, NPSR1, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.079E-09 | 3.917E-07 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.273E-08 | 5.157E-06 | ALPL, APEX1, CYP1A1, CYP1B1, DRD1, FLT3, HRH1, MAPK1, NFKB1, NOX4, SLC6A4 |
| BP | GO:0023052; signaling | GO:0007271; synaptic transmission, cholinergic | 2.812E-08 | 6.063E-06 | CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.106E-08 | 6.567E-06 | CA2, CA7, DRD1, DRD3, HTR2A, HTR2B, HTR2C, KDR, NPSR1 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.637E-08 | 7.615E-06 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.451E-07 | 2.634E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.451E-07 | 2.634E-05 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 3.620E-07 | 5.712E-05 | HTR2A, HTR2B, HTR2C |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.620E-07 | 5.712E-05 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.062E-07 | 6.318E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 5.433E-07 | 7.939E-05 | ADRA1D, ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.854E-07 | 1.316E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.040E-06 | 1.381E-04 | APEX1, AURKB, CDK1, CYP1A1, HTR2A, NOX4, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.180E-06 | 1.443E-04 | HTR2A, HTR2B, HTR2C, HTR6 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.180E-06 | 1.443E-04 | HTR2A, HTR2B, HTR2C, HTR6 |
| BP | GO:0009987; cellular process | GO:0010700; negative regulation of norepinephrine secretion | 2.012E-06 | 2.331E-04 | ADRA2A, ADRA2B, ADRA2C |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 2.012E-06 | 2.331E-04 | ADRA2A, ADRA2B, ADRA2C |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.446E-06 | 2.732E-04 | CYP1A1, HIF1A, LMNA, MMP2, NOX4, PKM, SLC6A4, TP53 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 2.819E-06 | 3.024E-04 | ADRA2A, ADRA2B, CDK1, FLT3, HTR2A, HTR2B, MAPK1, NOX4 |
| BP | Unclassified; | GO:0003056; regulation of vascular smooth muscle contraction | 3.011E-06 | 3.183E-04 | ADRA2B, CHRM1, CHRM3 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.912E-06 | 3.999E-04 | AHR, CSNK2A1, HIF1A, KDR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.291E-06 | 4.346E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 4.434E-06 | 4.435E-04 | ALPL, AXL, CA2, CSNK2A1, CYP1A1, CYP1A2, FLT3, HSD17B2, NFKB1, SLC6A4, TP53, TYR |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 4.440E-06 | 4.435E-04 | ADRA1D, ADRA2C, HRH1, HTR2A |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 5.669E-06 | 5.586E-04 | AXL, CDK1, CSNK2A1, FLT3, PKM |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 5.887E-06 | 5.748E-04 | HTR2A, HTR2B, HTR2C |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.343E-06 | 6.166E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 7.544E-06 | 7.236E-04 | ALOX12, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD17B1, HSD17B10, HSD17B2, KDM4E, NOX4, PKM, TYR |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 9.834E-06 | 9.112E-04 | ACHE, CHRM3, HSD17B1, IGF1R, PKM |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.015E-05 | 9.330E-04 | CYP19A1, HSD17B1, HSD17B2 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.041E-05 | 9.488E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 1.115E-05 | 1.003E-03 | HTR2A, HTR2C |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.115E-05 | 1.003E-03 | APEX1, POLB |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 1.115E-05 | 1.003E-03 | HTR2A, HTR2C |
| MF | Unclassified; | GO:0032403; protein complex binding | 1.175E-05 | 1.045E-03 | ACHE, ADRA2A, APEX1, FLT3, HTR2A, IGF1R, KDR, MMP12, MMP9, PKM, SLC6A4, TSHR |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 2.033E-05 | 1.652E-03 | DRD1, DRD3, HIF1A, HRH1 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.878E-05 | 2.238E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.338E-05 | 2.515E-03 | CA2, CA7 |
| MF | GO:0005215; transporter activity | GO:0005330; dopamine:sodium symporter activity | 3.338E-05 | 2.515E-03 | SLC6A2, SLC6A4 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.440E-05 | 2.574E-03 | ADRA2A, ADRA2B, ADRA2C, AXL, MAPK1 |
| CC | GO:0044456; synapse part | GO:0043679; axon terminus | 3.501E-05 | 2.611E-03 | ADRA2C, CHRM1, CHRM2, CHRM3 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 3.980E-05 | 2.928E-03 | DRD1, DRD3, HTR2A |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 4.414E-05 | 3.193E-03 | ADRA2C, CA2, CHRM1, CHRM2, CHRM3, DRD1, DRD3, HIF1A, HTR2A, HTR2B, HTR6, MAPK1, PKM, SLC6A2, SLC6A4 |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 4.625E-05 | 3.296E-03 | APEX1, CYP1A1, CYP1A2, KDM4E |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 4.632E-05 | 3.296E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.632E-05 | 3.296E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 5.077E-05 | 3.567E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 5.223E-05 | 3.657E-03 | HTR2A, HTR2B, HTR2C, KDR, NOX4, THPO |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 5.276E-05 | 3.682E-03 | APEX1, AXL, CDK1, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.138E-05 | 4.190E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 6.376E-05 | 4.325E-03 | ACHE, DRD1, HTR2A, SLC6A4 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.661E-05 | 4.491E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 6.777E-05 | 4.554E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 7.060E-05 | 4.716E-03 | APEX1, IGF1R, NFKB1, PKM, TP53, TSHR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.098E-05 | 4.726E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 7.428E-05 | 4.916E-03 | ACHE, ADRA2A, ADRA2C, CSNK2A1, ESR2, FLT3, IGF1R, KDR, MAPK1, MET, MMP9, NFKB1, PKM, SLC6A4, TP53, TYR |
| MF | GO:0003824; catalytic activity | GO:0004435; phosphatidylinositol phospholipase C activity | 1.004E-04 | 6.319E-03 | CHRM1, CHRM3, CHRM5 |
| BP | GO:0032501; multicellular organismal process | GO:0046541; saliva secretion | 1.108E-04 | 6.892E-03 | CHRM1, CHRM3 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.321E-04 | 7.968E-03 | APEX1, NOX4, SLC6A4, TP53, TYR |
| BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 1.364E-04 | 8.182E-03 | ACHE, HSD17B10, IGF1R, PKM, TP53 |
| BP | GO:0000003; reproduction | GO:0022414; reproductive process | 1.400E-04 | 8.329E-03 | ADRA2B, ADRA2C, ALPL, AXL, CDK1, CYP19A1, CYP1A1, DRD1, HIF1A, HSD17B2, MAPK1, MMP2, MMP9, SLC6A4 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.452E-04 | 8.544E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.528E-04 | 8.922E-03 | CYP1A2, MAPK1, MMP9 |
| BP | GO:0009987; cellular process | GO:0045744; negative regulation of G-protein coupled receptor protein signaling pathway | 1.528E-04 | 8.922E-03 | ADRA2A, DRD3, MET |
| MF | GO:0060089; molecular transducer activity | GO:0004969; histamine receptor activity | 1.658E-04 | 9.482E-03 | HRH1, HTR6 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.677E-04 | 9.536E-03 | ALPL, CYP1A1, TP53, TYR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.598E-17 | 2.701E-15 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5, HTR2B, HTR2C, ADRA1D, HTR2A, ADRA2C, ADRA2B, ADRA2A, TSHR, HTR6, HRH1, DRD1, DRD3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.355E-11 | 1.145E-09 | CHRM2, CHRM3, HTR6, HRH1, CHRM1, CHRM5, HTR2B, HTR2C, ADRA1D, HTR2A, DRD1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.322E-08 | 5.585E-07 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 7.155E-08 | 1.680E-06 | CHRM2, CHRM3, ACHE, CHRM1, CHRM4, CHRM5, MAPK1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 7.613E-08 | 1.680E-06 | HTR6, HTR2B, HTR2C, MAPK1, ALOX12, HTR2A, SLC6A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.300E-08 | 1.115E-06 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 7.952E-08 | 1.680E-06 | PKM, FLT3, MAPK1, TP53, MET, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 3.017E-07 | 5.099E-06 | MMP2, KDR, MAPK1, TP53, HIF1A, MMP9, MET, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.861E-09 | 1.048E-07 | CA12, CA2, CA4, CA7, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.741E-07 | 8.085E-06 | FLT3, MMP1, MMP2, MAPK1, HIF1A, MET, TP53, MMP9, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.122E-07 | 3.985E-06 | MMP1, MMP2, MAPK1, MMP9, TP53 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 4.095E-07 | 6.291E-06 | CDK1, HTR2B, HTR2C, MAPK1, HTR2A, DRD1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 3.712E-06 | 4.826E-05 | CHRM2, HTR6, CHRM1, MAPK1, DRD1, NFKB1, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.425E-05 | 1.720E-04 | CHRM2, CHRM1, KDR, MAPK1, TP53, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.668E-05 | 1.879E-04 | HRH1, HTR2B, HTR2C, ALOX12, HTR2A |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 5.382E-05 | 4.787E-04 | POLB, PKM, CDK1, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.945E-05 | 4.643E-04 | PIM1, CYP1B1, MAPK1, TP53, MMP9, MET, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.600E-05 | 2.746E-04 | FLT3, TP53, MMP9, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.526E-05 | 3.505E-04 | FLT3, PIM1, MAPK1, NFKB1 |
| 09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 6.830E-05 | 5.771E-04 | CHRM2, CHRM3, CHRM1, CHRM4, CHRM5, MAPK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.383E-05 | 6.746E-04 | MAPK1, TP53, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 2.107E-04 | 1.484E-03 | MAPK1, ADRA1D, ADRA2C, ADRA2B, ADRA2A |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.016E-04 | 1.482E-03 | MAPK1, TP53, NFKB1, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 9.855E-05 | 7.570E-04 | CSNK2A1, MAPK1, MET, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.275E-04 | 2.050E-03 | MMP2, PIM1, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.034E-04 | 1.972E-03 | MMP2, MAPK1, MMP9, ESR2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 8.558E-04 | 4.987E-03 | KDR, MAPK1, MET, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.529E-04 | 2.130E-03 | MAPK1, HIF1A, NFKB1, IGF1R |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.119E-03 | 6.301E-03 | LMNA, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.306E-03 | 6.493E-03 | MAPK1, TP53, MMP9, NFKB1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.009E-03 | 8.936E-03 | FUT7, PKM, HSD17B1, HSD17B2, CYP1A2, CYP1A1, ALPL, ALOX12, TYR, CYP19A1, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.239E-03 | 6.493E-03 | MAPK1, TP53, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.295E-03 | 6.493E-03 | MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.295E-03 | 6.493E-03 | MAPK1, MET, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.665E-03 | 7.914E-03 | MAPK1, NFKB1, ESR2 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.971E-04 | 1.972E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.733E-03 | 7.914E-03 | MAPK1, TP53, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.733E-03 | 7.914E-03 | CYP1A2, CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Seborrhea | L21 | CHRM3; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1; |
| J00-J99: Diseases of the respiratory system | Seasonal and perennial allergic rhinitis and vasomotor rhinitis | J30 | HRH1; |
| H00-H59: Diseases of the eye and adnexa | Mydriasis diagnosis | H57.0 | CHRM4; |
| NA: NA | Vertigo's disease | NA | HRH1; |
| H60-H95: Diseases of the ear and mastoid process | Vertigo meniere's disease | H81, H81.0, R42 | HRH1; |
| NA: NA | Vomiting | NA | HRH1; CHRM4; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | HRH1; |
| NA: NA | Morning sickness | NA | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; SLC6A4; |
| NA: NA | Moderate and severe psychomotor agitation | NA | CHRM4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Stabilize muscle contractions | M00-M99 | CHRM2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD3; CHRM1; CHRM5; HTR2A; HTR2C; HTR6; SLC6A4; |
| J00-J99: Diseases of the respiratory system | Hay fever | J30 | HRH1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ADRA2C; CHRM1; CHRM5; HTR2C; HTR6; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A2; SLC6A4; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C; CHRM4; |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | ADRA1D; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| NA: NA | Abdominal stomach pain | NA | CHRM1; |
| H00-H59: Diseases of the eye and adnexa | Acquired nystagmus | H55 | CHRM4; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ADRA2C; CHRM1; CHRM2; CHRM3; CHRM4; HTR6; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | SLC6A4; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| NA: NA | Dysuria | NA | CHRM4; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | CHRM5; |
| NA: NA | Menopausal staging | NA | SLC6A4; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| NA: NA | Meniere's disease | NA | HRH1; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1D; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1D; CYP19A1; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; TP53; |
| NA: NA | Common cold | NA | HRH1; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | ADRA1D; HTR2B; |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C; |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2; |
| NA: NA | Suprapubic pain | NA | CHRM4; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | CHRM1; CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; HTR2C; SLC6A4; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C; DRD3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Visceral spasms | R25.2 | CHRM1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Postoperative nausea and vomiting | R11 | CHRM3; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR2B; SLC6A4; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; CHRM1; CHRM3; CHRM4; CHRM5; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; SLC6A2; HTR2A; SLC6A4; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| NA: NA | Functional bowel syndrome | NA | CHRM1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | SLC6A4; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; CHRM2; HTR2A; |
| NA: NA | Schizoaffective disorders | NA | CHRM1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; TYR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fecal incontinence | R15 | ADRA1D; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; CHRM1; SLC6A4; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; HTR6; |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nocturia | R35 | CHRM4; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| NA: NA | Itching | NA | HRH1; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | CHRM1; CHRM4; CHRM5; HTR2B; |
| NA: NA | Excessive sweating | NA | CHRM1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | CHRM4; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; HRH1; MMP9; MAPK1; SLC6A4; TP53; MMP2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; SLC6A4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; HRH1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; DRD1; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depression | F32, F33 | SLC6A4; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; MMP2; |
| NA: NA | Extrapyramidal disorders secondary to neuroleptic drug therapy | NA | CHRM1; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; CHRM5; |
| NA: NA | Depressive disorders | NA | SLC6A4; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | CHRM4; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3; CHRM4; HTR6; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ADRA2C; HRH1; CHRM2; |
| NA: NA | Appetite suppressant | NA | SLC6A4; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; CHRM4; MMP9; MAPK1; PKM; TP53; MMP2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | SLC6A4; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HRH1; CHRM2; CHRM4; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | HRH1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| NA: NA | Dystonia | NA | CHRM1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | ADRA1D; |
| NA: NA | Chronic low back pain | NA | SLC6A4; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | CHRM1; CHRM3; CHRM4; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| N00-N99: Diseases of the genitourinary system | Overactive bladder | N32.81 | CHRM3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| K00-K95: Diseases of the digestive system | Colitis | K50-K52 | CHRM5; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; CHRM1; CHRM5; HTR6; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; DRD3; |
| C00-D49: Neoplasms | Pediatric cancer | C00-C96 | ADRA1D; |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C; CHRM1; CHRM2; CHRM4; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; ADRA2A; ADRA2C; SLC6A2; DRD1; HRH1; CHRM3; HTR2C; SLC6A4; PKM; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | CHRM4; HTR2A; |
| NA: NA | Peptic ulcer disease | NA | CHRM4; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; HRH1; CHRM1; CHRM2; CHRM4; SLC6A4; |
| NA: NA | Perennial and seasonal allergic rhinitis | NA | HRH1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | HRH1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Allergic skin disorders | L00-L99 | HRH1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; HRH1; CHRM5; |
| NA: NA | Allergic disorders | NA | HRH1; |
| C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | HRH1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Amnesia | F04 | CHRM5; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | CHRM4; CHRM5; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | HRH1; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; ADRA2C; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADRA1D; HTR2A; HTR2C; |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; ADRA2C; HTR2A; HTR2C; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| NA: NA | Chemotherapyinduced emesis | NA | SLC6A4; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Organophosphate poisoning | T60.0 | CHRM4; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1D; ADRA2C; DRD1; CHRM4; |
| NA: NA | Hypersensitivity reactions | NA | HRH1; |
| NA: NA | Coughs | NA | HRH1; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; SLC6A2; HRH1; HTR2A; HTR2C; HTR6; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnosing bronchial hyperreactivity | W88 | CHRM3; |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | HRH1; CHRM3; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| NA: NA | Respiratory allergies | NA | HRH1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| NA: NA | Gastritis | NA | CHRM4; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | CHRM4; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | HRH1; CHRM1; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADRA1D; ADRA2C; CHRM1; CHRM3; CHRM4; HTR2A; |
| NA: NA | GIST | NA | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD3; HTR2C; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | HRH1; |
| H00-H59: Diseases of the eye and adnexa | Produce mydriasis and cycloplegia for diagnostic purposes | H57.04 | CHRM4; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dry cough | R05 | HRH1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Brain diseases | G00-G99 | CHRM5; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| J00-J99: Diseases of the respiratory system | Obstructive lung diseases | J40-J44, J47 | CHRM3; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| NA: NA | Myalgia | NA | SLC6A4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Smoking cessation | F17.2 | SLC6A4; |
| NA: NA | Spasms | NA | CHRM3; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B; |
| NA: NA | Addiction | NA | CHRM2; HTR2A; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| NA: NA | Urticaria | NA | HRH1; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| NA: NA | Urgency | NA | CHRM4; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRA1D; CHRM1; CHRM2; CHRM3; CHRM5; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Urinary retention | R33 | CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH1; HTR2A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Sjogren's syndrome | M35.0 | CHRM3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | HRH1; CHRM4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; CHRM1; HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; SLC6A2; HRH1; CHRM4; HTR2A; HTR2B; HTR2C; SLC6A4; |
| NA: NA | Vasomotor rhinitis | NA | HRH1; |
| N00-N99: Diseases of the genitourinary system | Vasomotor symptoms | N95.1 | SLC6A4; |
| NA: NA | Uveitis | NA | CHRM4; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
